Related Experiment Video
Updated: Jul 18, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Pharmacokinetic alterations in obesity
Jane B Lee1, P Shane Winstead, Aaron M Cook
1UK HealthCare, Department of Pharmacy, University of Kentucky, Lexington, KY, USA.
Orthopedics
|December 1, 2006
Summary
Obesity significantly impacts how medications work, often requiring individualized dosing. More research is crucial to ensure safe and effective drug therapy for the growing obese population.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Obesity Medicine
Background:
- Obesity presents unique challenges in drug therapy due to altered pharmacokinetics.
- Established dosing guidelines for obesity are lacking for most medications.
- Variable pharmacokinetic changes in obese patients necessitate careful drug management.
Purpose of the Study:
- To highlight the critical need for individualized drug dosing in obese patients.
- To emphasize the variability in medication pharmacokinetics associated with obesity.
- To advocate for increased research into obesity's effects on drug metabolism and efficacy.
Main Methods:
- Review of existing literature on pharmacokinetics in obese populations.
- Analysis of challenges in applying standard dosing adjustments.
- Emphasis on clinical observation and pharmacotherapy monitoring.
Main Results:
- Pharmacokinetic alterations in obese individuals are highly variable.
- A one-size-fits-all approach to medication dosing in obesity is inappropriate.
- Current knowledge on drug dosing adjustments for obesity is limited.
Conclusions:
- Individualized drug dosing is essential for obese patients to achieve therapeutic levels and avoid toxicity.
- Practitioners must exercise caution and vigilant monitoring of pharmacotherapy in obese individuals.
- Further research is paramount to develop evidence-based dosing strategies for the growing obese population.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...